Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Cheng

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Cancer Epidemiology|February 10, 2015
The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot?Michael L Cheng, Li Zhang, Margaret Borok, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2019
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomasJacob M Sands, Tom Nguyen, Priyanka Shivdasani, et al.
JCO Precision Oncology|July 12, 2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLCMichael L Cheng, Christie J Lau, Marina S D Milan, et al.
Canadian Liver Journal|August 22, 2022
The 7th Canadian Symposium on Hepatitis C Virus: "Toward Elimination of HCV: How to Get There"Michael L Cheng, Mohamed S Abdel-Hakeem, Sophie E Cousineau, et al.
JCO Precision Oncology|January 7, 2022
Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLCMichael L Cheng, Marina S D Milan, Rubii M Tamen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2020
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung CancerBiagio Ricciuti, Gonzalo Recondo, Liam F Spurr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2024
A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid TumorsGregory M Cote, Bose S Kochupurakkal, Khanh Do, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2021
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint InhibitionJoao V Alessi, Biagio Ricciuti, Liam F Spurr, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid LeukemiaBogdan Popescu, Matthew F Jones, Madison Piao, et al.
JCO Precision Oncology|October 5, 2020
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement AnalysisYi Lee, Evan W Clark, Marina S D Milan, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Cancer Epidemiology|February 10, 2015
The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot?Michael L Cheng, Li Zhang, Margaret Borok, et al.
Lung Cancer (Amsterdam, Netherlands)|December 20, 2019
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomasJacob M Sands, Tom Nguyen, Priyanka Shivdasani, et al.
JCO Precision Oncology|July 12, 2021
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLCMichael L Cheng, Christie J Lau, Marina S D Milan, et al.
Canadian Liver Journal|August 22, 2022
The 7th Canadian Symposium on Hepatitis C Virus: "Toward Elimination of HCV: How to Get There"Michael L Cheng, Mohamed S Abdel-Hakeem, Sophie E Cousineau, et al.
JCO Precision Oncology|January 7, 2022
Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLCMichael L Cheng, Marina S D Milan, Rubii M Tamen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2020
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung CancerBiagio Ricciuti, Gonzalo Recondo, Liam F Spurr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2024
A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid TumorsGregory M Cote, Bose S Kochupurakkal, Khanh Do, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2021
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint InhibitionJoao V Alessi, Biagio Ricciuti, Liam F Spurr, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid LeukemiaBogdan Popescu, Matthew F Jones, Madison Piao, et al.
JCO Precision Oncology|October 5, 2020
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement AnalysisYi Lee, Evan W Clark, Marina S D Milan, et al.
Pageof 4